Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/1/2025

Timing and Administration Precautions for Fosamax and Levothyroxine

Critical Timing Requirements

  • The American College of Clinical Endocrinologists recommends taking levothyroxine first thing in the morning on an empty stomach, at least 30-60 minutes before any food, beverages, or other medications 2
  • The British Journal of Clinical Pharmacology suggests maintaining consistent timing daily to ensure stable thyroid hormone levels 3

Bone Health Considerations with Levothyroxine

  • The American Association of Clinical Endocrinologists notes that excessive levothyroxine dosing that suppresses TSH below normal range increases osteoporosis risk, particularly in postmenopausal women 3
  • The Journal of the American Medical Association found that subclinical hyperthyroidism from levothyroxine treatment results in significant loss of bone mineral density in postmenopausal women 3

Fosamax Treatment Protocol for This Population

  • The National Osteoporosis Foundation recommends treating with alendronate for 5 years as the standard duration for women with osteoporosis 1
  • The American College of Rheumatology suggests that alendronate reduces the relative risk of new vertebral, non-vertebral, and hip fractures compared to placebo 1
  • The Endocrine Society recommends ensuring adequate calcium intake (800-1000 mg/day) and vitamin D (800 IU/day) during bisphosphonate treatment 1
  • The American Dental Association advises completing any necessary dental work before initiating or continuing bisphosphonate therapy to reduce the risk of osteonecrosis of the jaw 4

Safety Monitoring

  • The FDA reports that osteonecrosis of the jaw occurs in 0.01-0.3% of users, with risk increasing with longer duration 5, 4
  • The National Institutes of Health found that atypical femoral fractures have an incidence of 3.0-9.8 cases per 100,000 patient-years, with risk escalating significantly after 5 years 4
  • High-quality evidence shows no differences in serious adverse events compared to placebo during the first 5 years of treatment 4